163 related articles for article (PubMed ID: 38572464)
1. Inflammatory bowel diseases and the clinical course of coronavirus disease 2019 - a Polish single-centre experience from the pre-vaccine era.
Banasik E; Dobrowolska A; Kołodziejczak B; Eder P
Prz Gastroenterol; 2023; 18(4):409-415. PubMed ID: 38572464
[TBL] [Abstract][Full Text] [Related]
2. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
3. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
[TBL] [Abstract][Full Text] [Related]
4. Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
Neri B; D'Agostini G; Salvatori S; Mossa M; Bettin F; Mancone R; Marafini I; Lolli E; Calabrese E; Monteleone G; Biancone L
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):948-954. PubMed ID: 37505974
[TBL] [Abstract][Full Text] [Related]
5. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain.
Guerra I; Algaba A; Jiménez L; Mar Aller M; Garza D; Bonillo D; Molina Esteban LM; Bermejo F
Inflamm Bowel Dis; 2021 Jan; 27(1):25-33. PubMed ID: 32830267
[TBL] [Abstract][Full Text] [Related]
6. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
[TBL] [Abstract][Full Text] [Related]
8. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.
Chebli JMF; Queiroz NSF; Damião AOMC; Chebli LA; Costa MHM; Parra RS
World J Gastroenterol; 2021 Mar; 27(11):1022-1042. PubMed ID: 33776370
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy.
Conti CB; Mainardi E; Soro S; Testa S; De Silvestri A; Drago A; Cereatti F; Grassia R
World J Gastrointest Endosc; 2022 Mar; 14(3):153-162. PubMed ID: 35432745
[TBL] [Abstract][Full Text] [Related]
10. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.
Mossa M; Neri B; Montesano L; Salvatori S; Marafini I; Scucchi L; Lolli E; Massoud R; Petruzziello C; Bernardini S; Calabrese E; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3787-3796. PubMed ID: 35647861
[TBL] [Abstract][Full Text] [Related]
12. Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.
Esposito S; Caminiti C; Giordano R; Argentiero A; Ramundo G; Principi N
Front Immunol; 2022; 13():933774. PubMed ID: 35812420
[TBL] [Abstract][Full Text] [Related]
13. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research.
Nakase H; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Wagatsuma K; Yokoyama Y; Hisamatsu T
Digestion; 2021; 102(5):814-822. PubMed ID: 32892197
[TBL] [Abstract][Full Text] [Related]
14. Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition.
Turner D; Huang Y; Martín-de-Carpi J; Aloi M; Focht G; Kang B; Zhou Y; Sanchez C; Kappelman MD; Uhlig HH; Pujol-Muncunill G; Ledder O; Lionetti P; Dias JA; Ruemmele FM; Russell RK;
J Pediatr Gastroenterol Nutr; 2020 Jun; 70(6):727-733. PubMed ID: 32443020
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic.
Vadan R; Iacob R; Costache R; Stroie T; Saizu IA; Iacob S; Gheorghe L; Diculescu M; Gheorghe C
J Gastrointestin Liver Dis; 2020 Dec; 29(4):549-553. PubMed ID: 33331349
[TBL] [Abstract][Full Text] [Related]
16. Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease.
Bosa L; Di Chiara C; Gaio P; Cosma C; Padoan A; Cozzani S; Perilongo G; Plebani M; Giaquinto C; Donà D; Cananzi M
Front Pediatr; 2022; 10():815857. PubMed ID: 35223697
[TBL] [Abstract][Full Text] [Related]
17. [The gastrointestinal effects of COVID–19 infection during childhood and among the children affected with inflammatory bowel disease].
Tóbi L; Prehoda B; Balogh A; Dezsőfi-Gottl A; Cseh Á
Orv Hetil; 2022 Feb; 163(6):214-221. PubMed ID: 35124570
[TBL] [Abstract][Full Text] [Related]
18. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
[TBL] [Abstract][Full Text] [Related]
19. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
[TBL] [Abstract][Full Text] [Related]
20. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
